CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?

Lisette B. W. Schröder¹ and Kerrie L. McDonald²*

¹ Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, Netherlands, ² Cure Brain Cancer Foundation Biomarkers and Translational Research Laboratory, Prince of Wales Clinical School, University of New South Wales, Kensington, NSW, Australia

Glioblastoma is aggressive, highly infiltrating, and the most frequent malignant form of brain cancer. With a median survival time of only 14.6 months, when treated with the standard of care, it is essential to find new therapeutic options. A specific CDK4/6 inhibitor, PD0332991, obtained accelerated approval from the Food and Drug Administration for the treatment of patients with advanced estrogen receptor-positive and HER2-negative breast cancer. Common alterations in the cyclin D1-cyclin-dependent kinase 4/6-retinoblastoma 1 pathway in glioblastoma make PD0332991 also an interesting drug for the treatment of glioblastoma. Promising results in in vitro studies, where patient derived glioblastoma cell lines showed sensitivity to PD0332991, gave motive to start in vivo studies. Outcomes of these studies have been contrasting in terms of PD0332991 efficacy within the brain: more research is necessary to conclude whether CDK4/6 inhibitor can be beneficial in the treatment of glioblastoma.

Keywords: glioblastoma, PD0332991, palbociclib, Rb1, CDK4/6, blood–brain barrier

INTRODUCTION

Glioblastoma (GBM, Astrocytoma grade IV) is an aggressive, highly infiltrating form of brain cancer. Glioblastoma accounts for 15.6% of all primary brain tumors and, representing 45.2%, it is the most frequent malignant brain tumor (1, 2). However, glioblastoma is an uncommon disease. With an incidence rate of 3.19 per 100,000 in the US, it occurs over 21 times less often than breast cancer (2, 3).

Today, the standard of care for glioblastoma consists of surgical resection followed by radiotherapy in combination with temozolomide (4). Significant improvements to the standard treatment leading to overall survival extension have been lacking. This devastating disease has a median survival time of only 14.6 months (4). It is, therefore, essential to find new therapeutic options. This review focuses on the data on PD0332991 (Palbociclib) studies in glioblastoma and how this drug can play a role in glioblastoma treatment.

THE CELL CYCLE

The normal cell cycle consists out of four phases, known as G1, S, G2, and M. Checkpoints regulate progression to the next phase or initiate apoptosis (5). The cyclin D1-cyclin-dependent kinase 4/6-retinoblastoma 1 (cycD1-CDK4/6-Rb1) signaling pathway covers an important checkpoint in the cell cycle (6). It regulates G1 progression to S phase by a cascade of (in)activations (7) (Figure 1).
The main players in the cycD1-CDK4/6-Rb1 pathway are CDK4/6, p16, p18, cycD1, Rb1, and E2F. Free CDK4/6 can be inactivated by p16/18, or bind to cycD1 (8–11). The CDK4/6-cycD1 complex phosphorylates the negative growth regulator Rb1 to inhibit it from binding transcription factor E2F (12). Free E2F can then ultimately cause cell division (13).

The importance of CDK4/6 in cell cycle control makes it an interesting target for cancer treatment (14). Alterations in cell's DNA can lead to cancer. These alterations cause cell division to be dysregulated, whereby the cell's mechanisms are not able to control cell growth. Hyperactivity and amplification of CDK4/6, even as their genomic instability, are mechanisms in which the origin of cell cycle dysregulation can be found (15).

**PD0332991**

PD0332991 is a highly specific CDK4/6 inhibitor (16) developed by Pfizer for cancer treatment (17). The drug inhibits CDK4/6, leading to inhibition of Rb1 phosphorylation and eventually to cell cycle blockage (18). PD0332991 has been a target of cancer research studies, especially within the field of breast cancer (19, 20). In 2004, Pfizer launched the first phase I clinical trial (ClinicalTrials.gov ID: NCT00141297). This trial was, in 2008, followed by a phase I/II clinical trial, named PALOMA-1, focusing on breast cancer treatment (21, 22). This clinical trial showed that PD0332991, as an addition to the breast cancer drug letrozole, significantly improved progression free survival for patients with advanced estrogen receptor-positive and HER2-negative breast cancer (22). Based on the results of this trial, PD0332991 obtained accelerated approval from the Food and Drug Administration (FDA) in the USA in 2015. The approval was specific to this subgroup of patients with breast cancer (23). Meanwhile, phase III trials for PD0332991 usage in breast cancer and phase I and II trials for PD0332991 treatment in other types of cancer have started (Table 1).

**TABLE 1 | Clinical trials for PD0332991.**

| Phase | Type of cancer   | Name               | ClinicalTrials.gov ID |
|-------|-----------------|--------------------|-----------------------|
| Phase I | Colorectal      | –                  | NCT01522989           |
|       | Central nervous system | – | NCT02255461          |
| Phase I/II | Lung       | –                  | NCT02022982           |
|       | Head and neck  | –                  | NCT02101034           |
| Phase II | Ovarian      | –                  | NCT01536743           |
|       | Prostate       | –                  | NCT02059213           |
|       | Glioblastoma   | –                  | NCT01227434           |
| Phase III | Breast     | PALOMA-2           | NCT01740427           |
|       | PALOMA-3       | –                  | NCT01942135           |
|       | PALOMA-4       | –                  | NCT02297438           |
|       | PENELLOPE-B    | –                  | NCT01864746           |
|       | PEARL          | –                  | NCT02028507           |

**Rb1 PREDICTS RESPONSE TO PD0332991**

Preclinical studies on PD0332991 in breast cancer have shown that Rb1 functioning is the determining factor for the efficacy of treatment (24–27). Rb1 deficiency or loss of its function results in PD0332991 resistance (24–27). Dean and colleagues, in 2010, compared Rb1-deficient to Rb1-proficient cell lines for differences in PD0332991 treatment response, whereby, in most cell lines, knockdown of Rb1 resulted in failure to stop proliferation through CDK4/6 inhibition (24). Consistent with these results, Roberts and colleagues observed in vivo that PD0332991 did not reduce tumor growth in mice harboring Rb1-deficient tumors (26). Witkiewicz and colleagues reconfirmed these outcomes with the in vitro testing of PD0332991 on Rb1 knockdown and control cells (27). In line with these results, it has been shown that changes in the cycD1-CDK4/6-Rb1 pathway, leading to elevated expression of Rb1, are most sensitive to PD0332991 treatment (28). These changes include higher levels of cycD1 and Rb1 and lower levels of p16 (28). Presumably, p16 and Rb1 can be used as markers to predict response to PD0332991 (25).

The Cancer Genome Atlas Research Network (TCGA) revealed in 2008 that the cycD1-CDK4/6-Rb1 pathway is, with alterations in 78.9% of glioblastoma, among the top three most altered pathways (29, 30). The p15/16 location, within this pathway, is the most common location for alteration (61%) (30). Other alterations found within the cycD1-CDK4/6-Rb1 pathway are CDK4/6 (15.5%), Rb1 (7.6%), p18 (5.6%), and cyclins (2%) (30). Most of these alterations promote the pathway, which makes this a suitable aim for therapy.

In 2010, Michaud and colleagues published the first article on PD0332991 use in glioblastoma (31). Through in vitro experiments, they revealed the same strengths and weaknesses of this drug as was found in breast cancer: PD0332991 inhibited cell proliferation in Rb1 proficient glioblastoma cells and Rb1 deficiency caused resistance (31). In addition, codeletion of p16 and p18 was, by Wiedemeyer and colleagues, found to be another predictor of increased sensitivity (32). A remarkable outcome of this study was that high levels of CDK4 or CDK6 had no influence on the sensitivity to PD0332991 (32). This data was supported with a later study by Cen and colleagues who further suggested that...
CDK4 amplification can be a sign of high resistance, while CDK6 amplification can be a sign of high sensitivity (33). Based on the genetic profiles of patient material, Verhaak and colleagues were able to define a classification, creating subtypes for glioblastoma (34). Codeletion of p16/18 was described to be highly associated with one of the subtypes: classical glioblastoma (34). It will be interesting to see in future experiments whether the classical subtype of glioblastoma gain most benefit from treatment with PD0332991.

In order to be an effective drug for glioblastoma, PD0332991 needs to have the ability to reach the tumor and thereby the ability to cross the blood–brain barrier (BBB). Studies have shown that PD0332991 is capable of crossing the BBB, but there are conflicting ideas on the effectivity of PD0332991 within the brain (31, 33, 35–37).

In 2010, Michaud and colleagues demonstrated that at a dose of 150 mg/kg/day, PD0332991 acted as an effective antiproliferative drug intracranially (31). The survival analysis, where survival time of PD0332991 treated mice was significantly extended compared to vehicle control mice, confirmed these findings (31). A study by Cen and colleagues strongly supported these findings by reconfirming the antiproliferative effect of PD0332991 in vivo and the survival benefit of treatment (33).

Recently, various research groups have revisited PD0332991 and its effects within the brain. In vitro experiments showed that PD0332991 is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), both efflux transporters in the BBB (35–38). Through in vivo experiments, de Gooijer and colleagues as well as Parrish and colleagues showed that P-gp and BCRP cause limited PD0332991 delivery to the brain, resulting in low drug concentrations (35, 36). Treated with 150 mg/kg/day, the restricted PD0332991 brain penetration was shown to be inadequate to reach antiproliferative effects or survival benefits (36). It is not clear as to why the research groups have come to different conclusions in regard to the ability of PD0332991 to cross the blood–brain barrier. Patient-derived cell lines were intracranially injected into immunocompromised all of the studies and the same concentration of PD0332991 was used (150 mg/kg/day). Further studies are warranted.

To determine the efficacy of PD0332991, the University of California in San Francisco had started a phase II clinical trial in patients with Rb1 positive, recurrent glioblastoma (Table 1). In December 2013, after 23 patients had been enrolled in this trial, the investigators completed collecting their final data for the primary outcome measure. We are still eagerly waiting for the results of this clinical trial.

Overall, PD0332991 appears to be an interesting drug for glioblastoma treatment and could be a valuable addition to the standard of care. Raub and colleagues have tested PD0332991 in combination with temozolomide and unpublished data from McDonald’s lab has shown significant efficacy using this CDK 4/6 inhibitor in combination with radiotherapy. In vivo studies with this combination have started. Although there is some irregularity in the outcomes concerning PD0332991 crossing the BBB, in vitro results are promising. New in vivo experiments, advised in combination with P-gp and BCRP inhibitors, are recommended before more clinical trials on glioblastoma patients start. The potential of PD0332991 in the treatment of glioblastoma is encouraging to continue investigating PD0332991 in the hope of ultimately finding a cure for this devastating disease.

AUTHOR CONTRIBUTIONS

LS conducted the scientific review and wrote the manuscript. KM reviewed the manuscript.

FUNDING

Cure Brain Cancer Foundation.

REFERENCES

1. World Health Organization. Glioblastoma. 4th ed. In: Louis DN, Ohgaki H, Wiestler OD, Cayoee WK, editors. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer (IARC) (2007). p. 33–49.

2. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol (2013) 15:111–56. doi:10.1093/neuonc/not151

3. Ferlay J, Soerjomataram I, Dikshit R, Mathers C, Rebelo M, Parkin DM, et al. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer, Lyon, France: World Health Organization (2013).

4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Trials: EORTC 26981-22922. N Engl J Med (2005) 352:2987–96. doi:10.1056/NEJMoa043330

5. Wang H, Zhang X, Tang L, Egerter SJ, DNA damage checkpoint recovery and cancer development. Exp Cell Res (2015) 334:350–8. doi:10.1016/j.yexcr.2015.03.011

6. Rabbitts TH, Bunnell D, Collyer GM, Esteller M, Ehrlich M, et al. CDK4 amplification triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell (1999) 98:859–69. doi:10.1016/S0092-8674(00)01819-6

7. Sherr CJ. G1 phase progression: cycling on cue. Cell (1994) 79:551–5. doi:10.1016/0092-8674(94)90540-1

8. Baldwin V, Lukas J, Marcotte MJ, Pagano M, Drettas M, Cyclin D1 is a nuclear protein required for cell cycle progression in G1, Genes Dev (1993) 7:812–21. doi:10.1101/gad.7.5.812

9. Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol (1993) 13:2077–86. doi:10.1128/MCB.13.3.2077

10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control. Nature (1993) 366:704–7. doi:10.1038/366704a0

11. More L, Chen D, Franklin D, Xiong Y, Chen-Kian S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(CDK4) and IL-6. Immunity (1997) 6:47–56. doi:10.1016/S1074-7613(00)80241-1

12. Matsushima H, Ewen ME, Stork DM, Kato J-Y, Hanks SK, Roussel MF, et al. Identification and properties of an atypical catalytic subunit (p345356-1cdk4) for mammalian D type G1 cyclins. Cell (1992) 71:323–34. doi:10.1016/0092-8674(92)90360-O

13. Chen H-Z, Rasi S-Y, Leong G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 9:785–97. doi:10.1038/nrc2696

14. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 9:153–66. doi:10.1038/nrc2602

15. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene (2014) 33:1890–903. doi:10.1038/onc.2013.137

16. Toogood PL, Harvey PJ, Repine JF, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem (2005) 48:2388–406. doi:10.1021/jm049354h
17. Pfizer (2015). IBRANCE (Palbociclib) Fact Sheet [Online]. Available from: https://www.pfizer.com/files/news/IBRANCE_Backgrounder_and_Development_Timeline_5_28_15.pdf
18. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated anti-tumor activity in human tumor xenografts. Mol Cancer Ther (2004) 3:1427–38.
19. Cadoo KA, Guacalp A, Traina TA. Palbociclib: an evidence-based n of its potential in the treatment of breast cancer. Breast Cancer Targets Ther (2014) 214:123–33. doi:10.2147/BCTT.S46725
20. Vidula N, Rugo HS. Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data. Clin Breast Cancer (2015). doi:10.1016/j.clbc.2015.07.005
21. Finn RS, Hurvitz S, Allison M, Applebaum S, Glasper J, DiCarlo B, et al. Phase I study of PD 0332991, a novel, oral, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole, for first-line treatment of metastatic post-menopausal, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Cancer Res (2009) 69:5069.
22. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol (2015) 16:25–35. doi:10.1016/S1470-2045(14)71159-3
23. Dhillon S. Palbociclib: first global approval. Drugs (2015) 75:543–51. doi:10.1007/s40266-015-0379-9
24. Dean JL, Thangavel C, McClendon AK, Rees CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene (2010) 29:4018–32. doi:10.1038/onc.2010.154
25. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Hum Cells (2012) 11:2179–86. doi:10.4116/cc.21195
26. Roberts PJ, Bisi JE, Strum JC, Combret AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 104:476–87. doi:10.1093/jnci/djs002
27. Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer (2014) 5:261–72.
28. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 11:R77.
29. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455:1061–8. doi:10.1038/nature07385
30. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell (2013) 155:462–77. doi:10.1016/j.cell.2013.09.034
31. Michaud K, Solomon DA, Oermann E, Kim J-S, Zhong W-Z, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 70:3228–38. doi:10.1158/0008-5472.CAN-09-4559
32. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA (2010) 107:11501–6. doi:10.1073/pnas.1001613107
33. Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mlaek AC, et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol (2012) 14:870–81. doi:10.1093/neuonc/nos114
34. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17:98–110. doi:10.1016/j.ccr.2009.12.020
35. de Gooyer MC, Zhang P, Thota N, Mayayo-Peralta I, Bui LCM, Beijnen JH, et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs (2015) 33:1012–9. doi:10.1007/s10637-015-0266-y
36. Parrish KE, Pokorny I, Mittapalli RK, Bakken K, Sarkaria JN, Elmqist WF. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model. J Pharmacol Exp Ther (2015) 355:263–71. doi:10.1124/jpet.115.228213
37. Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, et al. Brain exposure of two selective dual CDK4 and CDK6 Inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos (2015) 43:1360–71. doi:10.1124/dmd.114.082745
38. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, et al. Quantitative targeted absolute proteomics of human blood-brain barrier carrier receptors and transporters. J Neurochem (2011) 117:333–45. doi:10.1111/j.1471-4159.2011.07208.x

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Schröder and McDonald. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.